Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a net profit of 9.24 billion yuan in 2024, marking a significant turnaround from losses in previous years. Revenue is projected to reach 104.9 billion yuan, reflecting a year-on-year growth of 16.7% [2] - The core production metrics are continuously improving, with the comprehensive cost of raising pigs dropping to 14 yuan per kilogram in Q4 2024. The company plans to increase its pig sales target for 2025 to between 33 million and 35 million heads [2][3] - The company has also seen a steady increase in chicken output, with a total of 1.208 billion chickens raised in 2024, a 2.1% increase year-on-year. The comprehensive cost of chicken production decreased to 11.4 yuan per kilogram in Q4 2024 [3][4] Financial Summary - The company forecasts pig output of 30.18 million heads in 2024, increasing to 34 million heads in 2025 and 37 million heads in 2026. Chicken output is expected to rise from 1.208 billion in 2024 to 1.332 billion in 2026. Corresponding net profits are projected at 9.255 billion yuan for 2024, 12.349 billion yuan for 2025, and 11.183 billion yuan for 2026, with year-on-year growth rates of 244.9%, 33.4%, and -9.4% respectively [7] - The company's revenue is expected to grow from 89.921 billion yuan in 2023 to 105.169 billion yuan in 2024, with a year-on-year growth of 17%. The gross profit margin is projected to improve to 17% in 2024 [9]

Investment Rating - Investment Rating: Buy (Maintained) [2] Core Views - The company achieved revenue of 77.34 billion yuan in Q4 2024, representing a year-over-year increase of 21.8%. Adjusted net profit was 4.52 billion yuan, up 181.4% year-over-year, with growth potential driven by AI in gaming and advertising [5] - The long-term operational capability of the game "Three Kingdoms: Strategy" has been preliminarily validated, supporting sustained growth in the gaming business. The global market for SLG games is estimated at 70 billion yuan, with an average game lifespan exceeding 5 years [6] - Advertising business continues to show high growth, supported by core user growth. The company reported a DAU of 103 million, up 2.9% year-over-year, and a MAU of 340 million. Daily average usage time increased by 4.2% to 99 minutes, with daily video views exceeding 4.8 billion [7] - Revenue projections for 2025, 2026, and 2027 are 306.6 billion yuan, 336.2 billion yuan, and 359.6 billion yuan respectively, with adjusted net profits of 18.8 billion yuan, 33.2 billion yuan, and 40.4 billion yuan [7] Financial Summary - Total revenue for 2024 is projected at 26,832 million yuan, with a growth rate of 19%. Adjusted net profit is expected to be 1,878 million yuan in 2025, a significant increase from a loss of 39 million yuan in 2024 [9] - The company is expected to achieve an EPS (NON-GAAP) of 4.46 yuan in 2025, with a P/E ratio of 37.32 [10] - The gross margin is projected to improve from 32.7% in 2024 to 39.1% by 2026, indicating enhanced profitability [11]

Investment Rating - The report indicates a strong growth potential in the gene sequencing industry, with an expected market size exceeding 150 billion yuan by 2030, highlighting it as one of the fastest-growing sectors in in vitro diagnostics [30]. Core Insights - The gene sequencing market in China is projected to grow from 72 billion yuan in 2016 to 374 billion yuan by 2024, with a compound annual growth rate (CAGR) of 25.8% expected from 2025 to 2030 [30]. - The report emphasizes the transition from traditional sequencing methods to advanced fourth-generation sequencing technologies, which offer unique advantages such as ultra-long reads and real-time monitoring [4][20]. - The integration of AI models in processing and analyzing vast amounts of genetic data is identified as a key competitive advantage for companies in the industry [32]. Summary by Sections Gene Sequencing Definition and Classification - Gene sequencing is defined as a molecular biology technique used to determine the nucleotide sequence of DNA molecules, crucial for various fields including genetic disease diagnosis and personalized medicine [13][10]. - The classification of gene sequencing includes first, second, third, and fourth-generation technologies, with the fourth generation being the most advanced [11][17]. Development History and Characteristics of Gene Sequencing - The report outlines the evolution of gene sequencing technologies, highlighting the limitations of earlier methods and the advancements made in high-throughput sequencing [17]. - The cost of gene sequencing has significantly decreased, following Moore's Law, with the cost of whole genome sequencing dropping from 1 million USD in 2007 to under 100 USD in 2024 [19]. Market Size and Competitive Landscape - The gene sequencing market is expected to exceed 150 billion yuan by 2030, driven by its applications in clinical medicine and drug development [30]. - The report identifies key players in the market, including Illumina, Oxford Nanopore Technologies, and BGI, each with unique technological advantages and market strategies [43][46][48]. Key Companies in Gene Sequencing - Illumina is recognized as a leader in the gene sequencing technology space, known for its high-throughput sequencing systems that are widely used in genomics research [43]. - Oxford Nanopore Technologies specializes in fourth-generation sequencing technology, offering portable and flexible sequencing solutions [46]. - BGI is noted for its comprehensive capabilities in high-throughput sequencing and its recent legal victories that enhance its market position [48]. - Other notable companies include Berry Genomics, Dian Diagnostics, and Novogene, each contributing to advancements in gene sequencing and AI applications in clinical settings [49][52][54].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's FY25Q3 performance exceeded expectations with revenue of 280.2 billion yuan (yoy +8%), slightly above Bloomberg consensus by 1% [4] - Adjusted EBITDA and adjusted net profit reached 62.1 billion yuan (yoy +4%, margin 22%) and 51.1 billion yuan (yoy +6%, margin 18%), respectively, surpassing Bloomberg consensus by 2.7% and 12.2% [4] - The cloud business returned to double-digit growth, with revenue of 31.7 billion yuan (yoy +13%) and adjusted EBITA of 3.14 billion yuan (yoy +33%) [6] Summary by Sections Overall Performance - FY25Q3 revenue was 280.2 billion yuan, with a year-over-year increase of 8%, slightly above expectations [4] - Adjusted EBITDA was 62.1 billion yuan, with a margin of 22%, and adjusted net profit was 51.1 billion yuan, with a margin of 18% [4] Segment Performance - Taobao Group revenue was 136.1 billion yuan (yoy +5%), exceeding expectations by 3.3% [5] - Alibaba International Digital Commerce Group revenue was 37.8 billion yuan (yoy +32%), exceeding expectations by 4.4% [5] - Local Life Group revenue was 16.99 billion yuan (yoy +12%), slightly below expectations by 1.2% [5] - Cainiao Group revenue was 28.2 billion yuan (yoy -1%), below expectations by 9.9% [5] - Cloud Intelligence Group revenue was 31.7 billion yuan (yoy +13%), exceeding expectations by 3.1% [5] - Digital Entertainment Group revenue was 5.4 billion yuan (yoy +8%), exceeding expectations by 1.1% [5] - Other revenue was 53.1 billion yuan (yoy +13%), exceeding expectations by 7.1% [5] Growth Drivers - Taobao accelerated growth with revenue of 136.1 billion yuan, driven by GMV and take rate improvements [6] - The AIDC business is expected to achieve quarterly profitability next fiscal year [6] - The cloud business saw a resurgence with double-digit growth, and AI-related products maintained triple-digit growth for six consecutive quarters [6] Future Projections - Revenue projections for FY2025-2027 are 971.13 billion yuan, 983.82 billion yuan, and 1,088.52 billion yuan, with year-over-year growth of 3.2%, 1.3%, and 10.6% respectively [8] - Non-GAAP net profit projections are 159.96 billion yuan, 172.17 billion yuan, and 195.93 billion yuan, with year-over-year growth of 1.6%, 7.6%, and 13.8% respectively [8]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development. This provides new solutions for major challenges such as health, climate change, resource and energy security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [3][4]. Summary by Sections 1. Synthetic Biology Market Dynamics - The synthetic biology sector has shown strong performance, with a 14.67% increase in the index during the week of February 17-21, 2025, outperforming the Shanghai Composite Index by 13.70 percentage points [4][15]. - The top five performing companies in the synthetic biology sector during this period were Berry Genomics (+15%), BeiGene (+13%), Novogene (+13%), BGI Genomics (+12%), and Kasei Biotech (+11%) [17]. 2. Company Business Progress - The first phase of the Academy of Sciences Biotechnology Industrial Park project has been completed, with a production capacity of 5,000 tons of immune-regulating peptides and 20,000 tons of yeast cultivation, expected to generate an annual output value of 500 million yuan [21]. - Kasei Biotech's project for sustainable aviation fuel processing from waste oils has made significant progress, marking it as a key project in Henan Province for 2025 [21]. - The first production of 30,000 tons of synthetic biological products by Muyuan Foods has commenced, focusing on high-efficiency, low-consumption, and green biomanufacturing technology [21]. 3. Industry Financing Tracking - Synthetic biology companies are experiencing accelerated financing, with nearly a hundred companies completing new rounds of financing at the beginning of 2025. For instance, Ruide Lin Bio completed over 500 million yuan in Series C financing [26]. - Kynda, a German startup focused on sustainable protein production, successfully raised 300,000 euros in seed funding for developing fungal fermentation technology [26]. 4. Company R&D Directions - HAPO Pharmaceuticals and Insilico Medicine have formed a strategic partnership to advance AI-driven antibody drug development, leveraging their respective strengths in antibody discovery and AI technology [28]. - The project for producing 50,000 tons of polylactic acid fibers by Zhongtan and Bio-based Materials has received additional policy support, indicating a significant investment in sustainable materials [28]. 5. Industry Research Dynamics - A study published in "Cell" revealed insights into the evolution of CRISPR systems, providing important clues for understanding RNA-guided mechanisms in immune systems [32]. - Research in "Nature" successfully designed transmembrane fluorescent activating proteins, showcasing their activation capabilities in live cells [32].

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The report highlights the acceleration of AI development in China, with significant investments from cloud service providers driving downstream AI applications [3][4] - The performance of major indices shows a mixed trend, with the AI index experiencing a notable increase of 7.96% during the week [21] - The report emphasizes the importance of hardware investments in facilitating the deployment of cost-effective AI applications, particularly in the context of the ongoing US-China tech competition [4] Summary by Sections Market Review - From February 17 to February 21, 2025, the Shanghai Composite Index rose by 0.97%, while the ChiNext Index increased by 2.99%. The CSI 300 Index saw a 1% rise, and the Hang Seng Tech Index surged by 6.03% [21] - The AI index outperformed with a weekly increase of 7.96%, indicating strong market interest in AI-related stocks [21] AI Developments - On February 18, xAI launched the Grok3 model, which reportedly surpasses leading models like DeepSeekV3 and GPT-4o in core capabilities, with performance improvements of 16%-27% [3][38] - Tencent's AI application, Yuanbao, has seen a surge in downloads, reaching the second position in the Apple App Store in China, following the integration of the DeepSeek R1 model [3][39] Cloud Infrastructure Investment - Global cloud infrastructure spending is projected to grow by 20% year-on-year in Q4 2024, reaching $86 billion (approximately 623.48 billion RMB). Total spending for 2024 is expected to rise from $267.7 billion in 2023 to $321.3 billion (approximately 2.33 trillion RMB) [3] - The top three cloud service providers—AWS, Microsoft Azure, and Google Cloud—maintain a combined market share of 64%, with a year-on-year spending increase of 25% [3] Policy Support - The State-owned Assets Supervision and Administration Commission (SASAC) has emphasized the need for central enterprises to enhance AI development through increased funding and strategic investments [4] - Local governments, such as Shenzhen, are providing substantial financial incentives to support AI initiatives, including subsidies for training and model development [4] AI Hardware Innovations - Apple is set to launch the Apple Watch Ultra 3, which will be the company's first 5G-enabled smartwatch, enhancing its connectivity capabilities [41] - The price of quadruped robots is expected to drop to around 3,000-4,000 RMB, making them accessible to consumers [41]

[Table_StockNameRptType] 策略研究 月度报告 静水流深 [Table_RptDate] 报告日期： 2025-02-23 [Table_Author] 分析师：郑小霞 执业证书号：S0010520080007 电话：13391921291 邮箱：zhengxx@hazq.com 分析师：刘超 执业证书号：S0010520090001 电话：13269985073 邮箱：liuchao@hazq.com 分析师：张运智 执业证书号： S0010523070001 电话：13699270398 邮箱： zhangyz@hazq.com 分析师：任思雨 执业证书号： S0010523070003 电话：18501373409 邮箱： rensy@hazq.com 相关报告 3.策略周报《外部风险缓释提振市场， 弹性成长和季节性基建正当时》2025- 02-04 4.策略月报《正值春光好时节》2025- 01-26 主要观点： [Table_Summary] ⚫ 市场对"两会"政策的预期将回归现实，预计政府工作报告总体定 调将符合市场预期，同时经济基本面边际变化微弱，海外风险扰动 有限，因此市 ...

[Table_IndNameRptType] 农林牧渔de 行业周报 1 月能繁母猪存栏环比下降，白羽祖代更新量仅 1 万套 [Table_IndRank] 行业评级：增持 报告日期： 2025-2-22 行业指数与沪深 [Table_Chart] 300 走势比较 [Table_Author] 分析师：王莺 执业证书号：S0010520070003 邮箱：wangying@hazq.com [Table_Report] 相关报告 1.华安农业周报：1 月生猪补栏积极 性继续疲弱，美欧高致病性禽流感频 发 2025-2-8 2.华安农业周报：全国能繁母猪存栏 环比微降，出栏均重连续五周大降 2025-1-25 主要观点： _S本周生猪价格上涨 1%，1 月能繁母猪存栏量环比下降 0.39% ①本周生猪价格涨 1%至 14.73 元/公斤。本周六，全国生猪价格 14.73 元/公斤，周环比上涨 1%。涌益咨询（2.14-2.20）：全国 90 公斤内生猪出栏占比 4.34%，维持低位；50 公斤二元母猪价格 1641 元/头，连续四周持平；规模场 15 公斤仔猪出栏价 594 元/ 头，周环比下跌 5.7%；② ...

[Table_IndNameRptType] 农林牧渔 行业专题 猪价步入下行周期，成本下降仍是重中之重 [Table_IndRank] 行业评级：增持 报告日期： 2025-2-21 [Table_Chart] 行业指数与沪深 300 走势比较 执业证书号：S0010520070003 邮箱：wangying@hazq.com [Table_Report] 相关报告 1、生猪养殖行业系列报告十一：产能恢 复持续偏弱，2025 年猪价获有力支撑 20241116 2、生猪养殖行业系列报告十：产能恢复 明 显 偏 弱 ， 2025 年 猪 价 获 支 撑 20240926 3、生猪养殖行业系列报告九：产能去化 影响逐步显现，产能恢复明显偏弱 20240819 主要观点： ⚫[Table_Summary] 产能恢复明显偏慢，产业重组、融资稳步推进 本轮补栏积极性持续偏弱，从统计局数据看，2024Q2-Q4 全国能繁母 猪存栏量累计增幅 2.1%，2025 年 1 月全国能繁母猪存栏月环比下降 0.39%。上市猪企已成为新增产能主力军，2024 年 12 月末，牧原、 温氏的能繁母猪存栏量分别为 351.2 万头、 ...

医药生物 行业周报 行业评级：增持 报告日期： 2024-02-23 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 联系人：任婉莹 执业证书号：S0010123060034 邮箱：renwanying@hazq.com 联系人：刘洪飞 执业证书号：S0010123080001 邮箱：liuhongfei@hazq.com 相关报告 1.行业周报：持续看好医药的配置价 值 2024-02-27 2.行业周报：看好具备成长和估值相 得益彰的医药标的 2024-03-04 3.行业周报：医药本周回调较大，需 要关注"中药+创新落地的品类" 2024-03-11 4.行业周报：医药板块处于底部位 置，建议加大对医药的配置 2024- 07-01 5.行业周报：AI 破局医药板块 2025- 02-16 创新板块接力 AI 破局 主要观点： 本周行情回顾：板块上涨 本周医药生物指数上涨 1.88%，跑赢沪深 300 指数 0.87 个百分 点，跑赢上证综指 0.91 个百分点，行业涨跌幅排名第 9。2 月 21 日 （本周五），医药生物行业 PE（TTM，剔除负值）为 2 ...